BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29951790)

  • 1. Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.
    Sheng W; Kirschner-Hermanns R; Zhang H
    World J Urol; 2019 Feb; 37(2):317-325. PubMed ID: 29951790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local Therapy Improves Survival in Metastatic Prostate Cancer.
    Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
    Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population.
    Sheng W; Zhang H; Lu Y
    Int Urol Nephrol; 2018 Aug; 50(8):1435-1444. PubMed ID: 29982959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on survival of local treatment in patients with low prostate-specific antigen, high Gleason score prostate cancer: a population-based propensity score-matched analysis.
    Liu S; Wang XY; Huang TB; Niu Q; Yao K; Song X; Zhou SY; Chen Z; Zhou GC
    Ann Palliat Med; 2020 Jul; 9(4):1708-1717. PubMed ID: 32527134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis.
    Bandini M; Pompe RS; Marchioni M; Tian Z; Gandaglia G; Fossati N; Tilki D; Graefen M; Montorsi F; Shariat SF; Briganti A; Saad F; Karakiewicz PI
    World J Urol; 2018 Jan; 36(1):7-13. PubMed ID: 29063268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
    Pompe RS; Tilki D; Preisser F; Leyh-Bannurah SR; Bandini M; Marchioni M; Gild P; Tian Z; Fossati N; Cindolo L; Shariat SF; Huland H; Graefen M; Briganti A; Karakiewicz PI
    Prostate; 2018 Jul; 78(10):753-757. PubMed ID: 29663462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.
    Bandini M; Marchioni M; Preisser F; Zaffuto E; Tian Z; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    World J Urol; 2018 Sep; 36(9):1399-1407. PubMed ID: 29717358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses.
    Koo KC; Cho JS; Bang WJ; Lee SH; Cho SY; Kim SI; Kim SJ; Rha KH; Hong SJ; Chung BH
    Cancer Res Treat; 2018 Jan; 50(1):129-137. PubMed ID: 28279064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival and cancer-specific survival were improved in local treatment of metastatic prostate cancer.
    Miao Q; Wei Z; Liu C; Ye Y; Cheng G; Song Z; Chen K; Zhang Y; Chen J; Yue C; Ruan H; Zhang X
    Front Oncol; 2023; 13():1130680. PubMed ID: 37207146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.
    Gandaglia G; Sun M; Trinh QD; Becker A; Schiffmann J; Hu JC; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI; Abdollah F
    BJU Int; 2014 Dec; 114(6b):E62-E69. PubMed ID: 24467651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.
    Dell'Oglio P; Karnes RJ; Joniau S; Spahn M; Gontero P; Tosco L; Fossati N; Kneitz B; Chlosta P; Graefen M; Marchioro G; Bianchi M; Sanchez-Salas R; Karakiewicz PI; Poppel HV; Montorsi F; Briganti A;
    Urol Oncol; 2016 May; 34(5):234.e13-9. PubMed ID: 26706120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients.
    Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Fossati N; Gandaglia G; Gallina A; Abdollah F; Shariat SF; Montorsi F; Saad F; Tilki D; Briganti A; Karakiewicz PI
    Eur Urol Focus; 2019 May; 5(3):381-388. PubMed ID: 29366856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Outcomes for Metastatic Prostate Cancer Patients Treated With Radical Prostatectomy or Radiation Therapy: A SEER-based Study.
    Jin K; Qiu S; Jin H; Zheng X; Zhou X; Jin D; Li J; Yang L; Wei Q
    Clin Genitourin Cancer; 2020 Dec; 18(6):e705-e722. PubMed ID: 32763123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer.
    Chierigo F; Borghesi M; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Hoeh B; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Montorsi F; Chun FKH; Shariat SF; Mantica G; Suardi N; Terrone C; Karakiewicz PI
    Prostate; 2022 May; 82(6):740-750. PubMed ID: 35226380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
    Wenzel M; Würnschimmel C; Chierigo F; Tian Z; Shariat SF; Terrone C; Saad F; Tilki D; Graefen M; Mandel P; Kluth LA; Chun FKH; Karakiewicz PI
    Prostate; 2021 Aug; 81(11):728-735. PubMed ID: 34010465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer.
    Lee JY; Cho KS; Kwon JK; Jeh SU; Kang HW; Diaz RR; Ham WS; Koom WS; Keum KC; Choi YD
    Ann Surg Oncol; 2014 Nov; 21(12):4026-33. PubMed ID: 24841351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.
    Abdollah F; Sun M; Schmitges J; Tian Z; Jeldres C; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
    Eur Urol; 2011 Nov; 60(5):920-30. PubMed ID: 21741762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer.
    Petrovich Z; Lieskovsky G; Stein JP; Huberman M; Skinner DG
    BJU Int; 2002 Apr; 89(6):604-11. PubMed ID: 11942974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis.
    Hayashi N; Osaka K; Muraoka K; Hasumi H; Makiyama K; Kondo K; Nakaigawa N; Yao M; Mukai Y; Sugiura M; Takano S; Ito E; Kaizu H; Koike I; Hata M; Taguri M; Miyoshi Y; Izumi K; Kawahara T; Uemura H
    World J Urol; 2020 Oct; 38(10):2477-2484. PubMed ID: 31875247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.